RYZB

-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash plus a non-transferable contingent value right (CVR) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2 billion, a 97% premium to Fusion’s closing market price of $10.64 on March 18, 2024. Related Content: Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Says AstraZeneca Is Favorably Positioned. Combined, the upfront and maximum potential contingent value payments represent, if achie

15-12G - RayzeBio, Inc. (0001825367) (Filer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

SC 13G/A - RayzeBio, Inc. (0001825367) (Subject)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

4 - RayzeBio, Inc. (0001825367) (Issuer)

S-8 POS - RayzeBio, Inc. (0001825367) (Filer)

8-K - RayzeBio, Inc. (0001825367) (Filer)

25-NSE - RayzeBio, Inc. (0001825367) (Subject)

Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey

SC 14D9/A - RayzeBio, Inc. (0001825367) (Subject)

SC TO-T/A - RayzeBio, Inc. (0001825367) (Subject)

Bristol Myers Squibb (NYSE:BMY) today announced that its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of RayzeBio, Inc. (NASDAQ:RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the "Expiration Time"). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 53,052,499 shares of RazyeBio common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 86% of the issued and outstanding shares of RayzeBio common stock at th

Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on February 9, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240211117969/en/ Expiration of the waiting period under the HSR Act satisfies one of th